Michael Postow, MD
Memorial Sloan Kettering Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Michael Postow, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 00:05 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05289193 · CD8+ T Cell Imaging During Pre-surgery Immunotherapy in People With MelanomaMemorial Sloan Kettering Cancer Center · active not recruiting · Melanoma, Melanoma Stage III · principal investigator
- Ph2NCT03122522 · A Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination ImmunotherapyMemorial Sloan Kettering Cancer Center · active not recruiting · Metastatic Melanoma · principal investigator
- Ph1NCT03026517 · Clinical Trial of Phenformin in Combination With BRAF Inhibitor + MEK Inhibitor for Patients With BRAF-mutated MelanomaMemorial Sloan Kettering Cancer Center · completed · Melanoma · principal investigator
- Ph1NCT02659540 · Pilot Study of the Safety/Efficacy of Combination Checkpoint Blockade + External Beam Radiotherapy in Stage IV MelanomaLudwig Institute for Cancer Research · completed · Melanoma · study chair
- Ph2NCT01252251 · RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal MelanomaMemorial Sloan Kettering Cancer Center · completed · Uveal Melanoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 00:05 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.